Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

303 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PALLIA 10 score in phase I cancer studies.
Ouali K, Mateus C, Laparra A, Martin Romano P, Sampetrean A, Vuagnat P, Varga A, Champiat S, Verlingue L, Geraud A, Marabelle A, Hollebecque A, Gazzah A, Bahleda R, Postel Vinay S, Michot JM, Bernard-Tessier A, Bayle A, Ribrag V, Soria JC, Scotte F, Massard C, Pavliuc E, Baldini C. Ouali K, et al. Among authors: ribrag v. BMJ Support Palliat Care. 2022 Aug 30:bmjspcare-2022-003601. doi: 10.1136/spcare-2022-003601. Online ahead of print. BMJ Support Palliat Care. 2022. PMID: 36041820
Tumour growth rates and RECIST criteria in early drug development.
Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferté C, Massard C, Soria JC. Gomez-Roca C, et al. Among authors: ribrag v. Eur J Cancer. 2011 Nov;47(17):2512-6. doi: 10.1016/j.ejca.2011.06.012. Epub 2011 Jul 15. Eur J Cancer. 2011. PMID: 21763126
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.
Gomez-Roca CA, Lacroix L, Massard C, De Baere T, Deschamps F, Pramod R, Bahleda R, Deutsch E, Bourgier C, Angevin E, Lazar V, Ribrag V, Koscielny S, Chami L, Lassau N, Dromain C, Robert C, Routier E, Armand JP, Soria JC. Gomez-Roca CA, et al. Among authors: ribrag v. Ann Oncol. 2012 May;23(5):1301-1306. doi: 10.1093/annonc/mdr383. Epub 2011 Sep 14. Ann Oncol. 2012. PMID: 21917737 Free article.
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, Zitvogel L, Chaput N, Paci A. Pautier P, et al. Among authors: ribrag v. Oncoimmunology. 2013 Feb 1;2(2):e23079. doi: 10.4161/onci.23079. Oncoimmunology. 2013. PMID: 23525192 Free PMC article.
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
Hollebecque A, Deutsch E, Massard C, Gomez-Roca C, Bahleda R, Ribrag V, Bourgier C, Lazar V, Lacroix L, Gazzah A, Varga A, de Baere T, Beier F, Kroesser S, Trang K, Zenke FT, Klevesath M, Soria JC. Hollebecque A, et al. Among authors: ribrag v. Invest New Drugs. 2013 Dec;31(6):1530-8. doi: 10.1007/s10637-013-0026-9. Invest New Drugs. 2013. PMID: 24077982 Clinical Trial.
Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Michot JM, Mazeron R, Danu A, Lazarovici J, Ghez D, Antosikova A, Willekens C, Chamseddine AN, Minard V, Dartigues P, Bosq J, Carde P, Koscielny S, De Botton S, Ferme C, Girinsky T, Ribrag V. Michot JM, et al. Among authors: ribrag v. Eur J Cancer. 2015 Nov;51(16):2386-95. doi: 10.1016/j.ejca.2015.07.009. Epub 2015 Aug 5. Eur J Cancer. 2015. PMID: 26254810
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Michot JM, et al. Among authors: ribrag v. Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Eur J Cancer. 2016. PMID: 26765102 Review.
303 results